AVEO Pharmaceuticals, Inc. (AVEO)
| Market Cap | 521.45M |
| Revenue (ttm) | 94.32M |
| Net Income (ttm) | -29.04M |
| Shares Out | 34.76M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | 48.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 245,298 |
| Open | 15.00 |
| Previous Close | 15.00 |
| Day's Range | 14.99 - 15.00 |
| 52-Week Range | 3.06 - 15.00 |
| Beta | 0.98 |
| Analysts | Sell |
| Price Target | 15.30 (+2.0%) |
| Earnings Date | Mar 13, 2023 |
About AVEO
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In a... [Read more]
Financial Performance
In 2021, AVEO's revenue was $42.30 million, an increase of 602.69% compared to the previous year's $6.02 million. Losses were -$53.34 million, 49.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AVEO stock is "Sell." The 12-month stock price forecast is $15.3, which is an increase of 2.00% from the latest price.
News
LG Chem Completes Acquisition of AVEO Oncology
AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division AVEO to Become the U.S. Foundation for LG Chem Life Sciences' Oncology Division
AVEO Oncology Stockholders Approve Acquisition by LG Chem
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better ...
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVEO Stockholders Vote “FOR” the Transaction Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend that AVE...
4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AVEO Oncology Reports Third Quarter 2022 Financial Results
– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue –
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of AVEO Pharmaceuticals, Inc. - AVEO
NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm ra...
SHAREHOLDER ALERT: Weiss Law Investigates AVEO Pharmaceuticals, Inc.
NEW YORK , Oct. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AVEO Pharmaceuticals, Inc. ("AVEO" or t...
AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023.
AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVEO Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - October 18, 2022) - Rigrodsky Law, P.A. is investigating AVEO Pharmaceuticals, Inc. ("AVEO") (NASDAQ CM: AVEO) regarding possible breaches of fiduciary duties a...
LG Chem to acquire AVEO Oncology for $566 million
Yahoo Finance anchor Brad Smith breaks down how markets are trading, plus why AVEO stock is soaring today.
Shareholder Alert: Ademi LLP investigates whether AVEO Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with LG Chem
MILWAUKEE , Oct. 18, 2022 /PRNewswire/ -- Ademi LLP is investigating AVEO (NASDAQ: AVEO) for possible breaches of fiduciary duty and other violations of law in its transaction with LG Chem. Click her...
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
AVEO Oncology (NASDAQ: AVEO) stock jumped 40% in premarket trading after LG Chem (OTCMKTS:LGCLF) said it would buy the company for $15/share in cash. The price implies a value of $566 million for AVE...
AVEO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of AVEO Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) to LG Chem, Ltd.
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
SEOUL, South Korea and CAMBRIDGE, Mass. and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) and AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-...
S.Korea's LG Chem to invest $566 mln to acquire U.S. Aveo Pharmaceuticals
South Korea's LG Chem Ltd said in a regulatory filing on Tuesday that it is investing $566 million to acquire U.S. firm Aveo Pharmaceuticals Inc and enter the U.S. anti-cancer drug market.
3 Breakout Stocks to Keep an Eye on for Solid Returns
Par Pacific (PARR), AVEO Pharmaceuticals (AVEO) and Heritage Commerce Corp (HTBK) have been selected as the breakout stocks for today.
U.S. Patent & Trademark Office Allows AVEO Oncology's Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for ...
Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.